FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2974841401> ?p ?o ?g. }

• W2974841401 endingPage "914" @default.
• W2974841401 startingPage "903" @default.
• W2974841401 abstract "Depression is usually managed in primary care, but most antidepressant trials are of patients from secondary care mental health services, with eligibility criteria based on diagnosis and severity of depressive symptoms. Antidepressants are now used in a much wider group of people than in previous regulatory trials. We investigated the clinical effectiveness of sertraline in patients in primary care with depressive symptoms ranging from mild to severe and tested the role of severity and duration in treatment response.The PANDA study was a pragmatic, multicentre, double-blind, placebo-controlled randomised trial of patients from 179 primary care surgeries in four UK cities (Bristol, Liverpool, London, and York). We included patients aged 18 to 74 years who had depressive symptoms of any severity or duration in the past 2 years, where there was clinical uncertainty about the benefit of an antidepressant. This strategy was designed to improve the generalisability of our sample to current use of antidepressants within primary care. Patients were randomly assigned (1:1) with a remote computer-generated code to sertraline or placebo, and were stratified by severity, duration, and site with random block length. Patients received one capsule (sertraline 50 mg or placebo orally) daily for one week then two capsules daily for up to 11 weeks, consistent with evidence on optimal dosages for efficacy and acceptability. The primary outcome was depressive symptoms 6 weeks after randomisation, measured by Patient Health Questionnaire, 9-item version (PHQ-9) scores. Secondary outcomes at 2, 6 and 12 weeks were depressive symptoms and remission (PHQ-9 and Beck Depression Inventory-II), generalised anxiety symptoms (Generalised Anxiety Disorder Assessment 7-item version), mental and physical health-related quality of life (12-item Short-Form Health Survey), and self-reported improvement. All analyses compared groups as randomised (intention-to-treat). The study is registered with EudraCT, 2013-003440-22 (protocol number 13/0413; version 6.1) and ISRCTN, ISRCTN84544741, and is closed to new participants.Between Jan 1, 2015, and Aug 31, 2017, we recruited and randomly assigned 655 patients-326 (50%) to sertraline and 329 (50%) to placebo. Two patients in the sertraline group did not complete a substantial proportion of the baseline assessment and were excluded, leaving 653 patients in total. Due to attrition, primary outcome analyses were of 550 patients (266 in the sertraline group and 284 in the placebo group; 85% follow-up that did not differ by treatment allocation). We found no evidence that sertraline led to a clinically meaningful reduction in depressive symptoms at 6 weeks. The mean 6-week PHQ-9 score was 7·98 (SD 5·63) in the sertraline group and 8·76 (5·86) in the placebo group (adjusted proportional difference 0·95, 95% CI 0·85-1·07; p=0·41). However, for secondary outcomes, we found evidence that sertraline led to reduced anxiety symptoms, better mental (but not physical) health-related quality of life, and self-reported improvements in mental health. We observed weak evidence that depressive symptoms were reduced by sertraline at 12 weeks. We recorded seven adverse events-four for sertraline and three for placebo, and adverse events did not differ by treatment allocation. Three adverse events were classified as serious-two in the sertraline group and one in the placebo group. One serious adverse event in the sertraline group was classified as possibly related to study medication.Sertraline is unlikely to reduce depressive symptoms within 6 weeks in primary care but we observed improvements in anxiety, quality of life, and self-rated mental health, which are likely to be clinically important. Our findings support the prescription of SSRI antidepressants in a wider group of participants than previously thought, including those with mild to moderate symptoms who do not meet diagnostic criteria for depression or generalised anxiety disorder.National Institute for Health Research." @default.
• W2974841401 created "2019-09-26" @default.
• W2974841401 creator A5001682107 @default.
• W2974841401 creator A5006410830 @default.
• W2974841401 creator A5006966400 @default.
• W2974841401 creator A5016704933 @default.
• W2974841401 creator A5019176918 @default.
• W2974841401 creator A5023414629 @default.
• W2974841401 creator A5037242114 @default.
• W2974841401 creator A5043515094 @default.
• W2974841401 creator A5046339293 @default.
• W2974841401 creator A5048461202 @default.
• W2974841401 creator A5049038959 @default.
• W2974841401 creator A5055543220 @default.
• W2974841401 creator A5057405954 @default.
• W2974841401 creator A5063003754 @default.
• W2974841401 creator A5065647766 @default.
• W2974841401 creator A5067823734 @default.
• W2974841401 creator A5069618968 @default.
• W2974841401 creator A5070136704 @default.
• W2974841401 creator A5072246651 @default.
• W2974841401 creator A5074484228 @default.
• W2974841401 creator A5078660144 @default.
• W2974841401 creator A5079519429 @default.
• W2974841401 creator A5080028737 @default.
• W2974841401 creator A5083791593 @default.
• W2974841401 creator A5085404772 @default.
• W2974841401 creator A5086670553 @default.
• W2974841401 creator A5088273242 @default.
• W2974841401 creator A5089632060 @default.
• W2974841401 date "2019-11-01" @default.
• W2974841401 modified "2023-10-16" @default.
• W2974841401 title "The clinical effectiveness of sertraline in primary care and the role of depression severity and duration (PANDA): a pragmatic, double-blind, placebo-controlled randomised trial" @default.
• W2974841401 cites W140784171 @default.
• W2974841401 cites W1480729244 @default.
• W2974841401 cites W1870888192 @default.
• W2974841401 cites W1968895338 @default.
• W2974841401 cites W1992703315 @default.
• W2974841401 cites W1995788203 @default.
• W2974841401 cites W2004762037 @default.
• W2974841401 cites W2011021576 @default.
• W2974841401 cites W2018511754 @default.
• W2974841401 cites W2024598568 @default.
• W2974841401 cites W2034555052 @default.
• W2974841401 cites W2036397809 @default.
• W2974841401 cites W2037569408 @default.
• W2974841401 cites W2041927436 @default.
• W2974841401 cites W2042603438 @default.
• W2974841401 cites W2054931962 @default.
• W2974841401 cites W2058332740 @default.
• W2974841401 cites W2059190479 @default.
• W2974841401 cites W2062363236 @default.
• W2974841401 cites W2065974896 @default.
• W2974841401 cites W2067550068 @default.
• W2974841401 cites W2072968785 @default.
• W2974841401 cites W2094608167 @default.
• W2974841401 cites W2097893571 @default.
• W2974841401 cites W2101568855 @default.
• W2974841401 cites W2102151931 @default.
• W2974841401 cites W2120609469 @default.
• W2974841401 cites W2127446711 @default.
• W2974841401 cites W2128283668 @default.
• W2974841401 cites W2132322340 @default.
• W2974841401 cites W2140815719 @default.
• W2974841401 cites W2141487393 @default.
• W2974841401 cites W2145618858 @default.
• W2974841401 cites W2153403353 @default.
• W2974841401 cites W2153621599 @default.
• W2974841401 cites W2155959499 @default.
• W2974841401 cites W2169679251 @default.
• W2974841401 cites W2170351571 @default.
• W2974841401 cites W2301596470 @default.
• W2974841401 cites W2402566006 @default.
• W2974841401 cites W2565743671 @default.
• W2974841401 cites W2574192814 @default.
• W2974841401 cites W2579967741 @default.
• W2974841401 cites W2610232737 @default.
• W2974841401 cites W2765822240 @default.
• W2974841401 cites W2788337440 @default.
• W2974841401 cites W2795956833 @default.
• W2974841401 cites W2948548704 @default.
• W2974841401 cites W2959164882 @default.
• W2974841401 cites W2990290481 @default.
• W2974841401 cites W4248434449 @default.
• W2974841401 doi "https://doi.org/10.1016/s2215-0366(19)30366-9" @default.
• W2974841401 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7029306" @default.
• W2974841401 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31543474" @default.
• W2974841401 hasPublicationYear "2019" @default.
• W2974841401 type Work @default.
• W2974841401 sameAs 2974841401 @default.
• W2974841401 citedByCount "74" @default.
• W2974841401 countsByYear W29748414012019 @default.
• W2974841401 countsByYear W29748414012020 @default.
• W2974841401 countsByYear W29748414012021 @default.
• W2974841401 countsByYear W29748414012022 @default.
• W2974841401 countsByYear W29748414012023 @default.
• W2974841401 crossrefType "journal-article" @default.
• W2974841401 hasAuthorship W2974841401A5001682107 @default.

• next